Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
Wednesday, July 22, 2026 1 min read
Key Takeaway: Summit Therapeutics Inc. has reported updated overall survival results from the Phase III HARMONi trial, demonstrating that ivonescimab combined with platinum-doublet chemotherapy continues to show a favorable trend. The results indicate consistent efficacy and safety across both Asian and western patient populations compared to chemotherapy alone.
Positive efficacy and safety profile observed in diverse patient groups.
Potential first-in-class bispecific antibody could change treatment landscape.
Full Press Release Details
MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced results of an updated overall survival (OS) analysis from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab. Ivonescimab plus platinum-doublet chemotherapy in this trial continues to show a positive OS trend and a consistent efficacy and safety profile in Asian and western patients when compared to chemotherapy alone. The HARMONi
Frequently Asked Questions
What is ivonescimab?
Ivonescimab is a novel bispecific antibody being investigated for its potential in cancer treatment.
What were the results of the HARMONi study?
The study showed a positive overall survival trend for ivonescimab plus chemotherapy compared to chemotherapy alone.
Who participated in the HARMONi trial?
The trial included both Asian and western patients to assess the efficacy and safety of ivonescimab.
What type of chemotherapy was used in the trial?
The trial utilized platinum-doublet chemotherapy in combination with ivonescimab.